古巴，法国同意对乙型肝炎疫苗的发展

StephenW

                                                                                                                                   Cuba, France Agree on Development of Hepatitis B Vaccine                                                                                                                       

By Carmen Esquivel Sarria Paris, Feb 12 (Prensa Latina) French company Abivax and the Center for  Genetic Engineering and Biotechnology (CIGB) in Cuba announced an  agreement here today to partner in the development and commercialization  of vaccines, among them, one against the Hepatitis B virus. The CIGB, Cuba's leading biotechnology institution, has more than 50 research-development projects, while Abivax, based in Paris, is a product of the merger of the Wittycell, Splicos and Zophis firms. Their objective is to fight infectious diseases and cancer. "Cuba is known for the excellence of its physicians and the quality of its vaccines. This is a project of international importance to put France foremost in this matter," Philippe Pouletty, president of the Administrative Council of the French firm, said. Simultaneously, Norkis Arteaga, head of Biocubafarma business department, stated that the complementary nature of both companies in research and production will allow for the distribution of many products in the future. In statements to Prensa Latina, Arteaga spoke of a licensing agreement between the CIGB and Abivax for the development and commercialization of the therapeutic vaccine against Hepatitis B. Cuba will provide the clinical results and capacity, while the French firm the financial resources to complete other clinical trials not only in Europe but also in Asia, along with the experience to register it in these markets and commercialize it later, he said.

StephenW

Paris ， 2月12日（ Prensa拉提纳）法国公司Abivax和中心遗传工程和生物技术（ CIGB ）在古巴今天宣布一项协议，这里在疫苗的开发和商业化，其中，1人反对乙肝病毒合作伙伴。
该CIGB ，古巴领先的生物技术机构，拥有超过50个研究开发项目，同时Abivax ，总部设在巴黎，是Wittycell ， Splicos和Zophis企业合并的产物。他们的目标是防治各种传染病和癌症。

“古巴是著名的其医师的卓越和其疫苗的质量，这是具有国际意义的一个项目，把法国最重要的在这个问题上， ”菲利普Pouletty ，这家法国公司的行政理事会的总裁，他说。

同时， Norkis亚加， Biocubafarma营业部负责人表示，两家公司在研究和生产的互补性将允许许多产品在未来的分布。

在报表Prensa拉提纳，亚加谈到对乙型肝炎治疗性疫苗的开发和商业化的CIGB和Abivax之间的许可协议

古巴将提供临床效果和能力，而法国公司的财务资源来完成，不仅在欧洲，而且在亚洲的其他临床试验中，随着经验的注册它在这些市场，后来商业化，他说。

StephenW

我相信这是NASVAC.
一篇论文将在下个月APASL提交.

咬牙硬挺

感谢分享，好消息啊

StephenW

回复 咬牙硬挺 的帖子

非常好的消息.

9病成医

真是个好消息。在古巴搞临床实验，效率应该高很多。

StephenW

French pharma startup to test and sell Cuban vaccines                     Email This Post                 

Philippe Pouletty, serial life science entrepreneur              Photo: Courtesy Truffle Capital

CUBA STANDARD — In a rare Europe-based Cuban R&D partnership, the Center for Genetic Engineering and Biotechnology (CIGB) partnered with a new company formed by French equity investment firm Truffle Capital, licensing a therapeutic vaccine for chronic hepatitis B for sale in markets in Europe and Asia, for starters.
Under the agreement, CIGB will manufacture the hepatitis B vaccine in Cuba, for sale in Europe, Asia and elsewhere, once it is approved there.
“As long as CIGB can scale up and meet quality requirements, Cuba wil continue to exclusively manufacture and supply the vaccine,” Truffle co-founder and ABIVAX Chairman Philippe Pouletty told Cuba Standard. He declined to specify which markets are covered by the licensing agreement.
Truffle said in a press release it merged three French life sciences companies to form ABIVAX, which the investors would like to become “a global leader” in therapeutic vaccines and antivirals. Founded in December, Paris-based ABIVAX has two therapeutic vaccines under development and is in negotiations over more acquisitions.
Poulletty said he hoped CIGB will contribute more products to ABIVAX’ pipeline, but he declined to specify them.
“At Truffle Capital, we are proud to have founded ABIVAX after two years of discussion with Cuba, which is known for its excellent physicians and high-quality vaccines,” Pouletty said in the press release. “This is an international project that is intended to place France and Cuba at the forefront of progress in the field of therapeutic vaccines.”
CIGB, the largest subsidiary of state holding BioCubaFarma, has partnered with companies in China, India, Canada and Brazil, but this is its first such cooperation in European markets. When signing the licensing agreement with ABIVAX executives in Havana this week, Norkis Arteaga Morales, business development director of BioCubaFarma, told Prensa Latina that CIGB will contribute the hepatitis B vaccine, which it already sells in various markets around the globe, and its production capacities, while Truffle will contribute the capital to complete clinical studies in Europe and Asia, as well as its marketing resources.
CIGB products are sold in ALBA member nations Venezuela, Ecuador, Bolivia and Nicaragua, as well as in Brazil, China, Vietnam and Angola, among others.
“Our complementary skills in both R&D and production will enable us to take several vaccines into international markets in the years to come”, Arteaga said, according to Prensa Latina.
Pouletty told Cuba Standard that BioCubaFarma did not want to form a joint venture this time, but added that ABIVAX has a “very open spirit to future collaboration.”
Truffle Capital is a 13-year old independent venture capital firm with €550 million ($754 million) under management and advisory, specializing in energy, information technology and life sciences companies. The firm is led by a team of four general partners, Philippe Pouletty, Jean-François Fourt, Henri Moulard, and Bernard-Louis Roques.
Pouletty’s track record includes founding and developing life science companies such as Deinove (Alternext: ALDEI), Carbios, Carmat (Alternext: ALCAR), Neovacs (Alternext: ALNEV), Splicos, Pharnext, Plasmaprime, Vexim, and Wittycell. He holds 29 patents, including the second highest revenue generating life science patent for Stanford University, and was inducted in the Stanford University Hall of Fame of Inventors in 2012. He has an MD from the University of Paris VI, and is a former chairman of France Biotech, the French biotech industry association.

Hecho en Cuba -- CIGB will produce the drug at its facility in Havana

The three French biotech companies Truffle put together to form ABIVAX are Wittycell, Splicos and Zophis.
CIGB, which specializes in the discovery, development and production of vaccines and antivirals, has already been working with Wittycell on getting the hepatitis B vaccine to market. The vaccine is in Phase IIb clinical trial in patients with chronic hepatitis B, which leads to cirrhosis and liver cancer.
Pouletty made his first contact with CIGB in South Africa four years ago, and he said he was impressed by Cuba’s biotechnology prowess. Two years ago, his company began negotiations with CIGB.
“It took some time to reach a mutually beneficial agreement,” he said. “It’s a process that can be relatively complex.”
Other ABIVAX products under development include an anti-viral drug for AIDS from Splicos, an anti-HPV        therapeutic vaccine to treat uterine cervix dysplasia        and prevent the emergence of cancer from Wittycell, and an adjuvant to        boost NKT and B cell response from Wittycell.

StephenW

法国制药启动测试和古巴出售疫苗
通过电子邮件发送电子邮件发送邮

菲利普Pouletty ，串口生命科学企业家图文：礼貌松露资本

CUBA标准 - 在一次罕见的以欧洲为基地的古巴研发合作伙伴关系，该中心遗传工程和生物技术（ CIGB ）伙拍法国股权投资公司松露资本成立了一家新公司，授权一个治疗性疫苗的销售慢性乙型肝炎在市场欧洲和亚洲，对于初学者。

根据协议， CIGB将生产乙肝疫苗在古巴，销售在欧洲，亚洲和其他地方，一旦它被批准那里。

“只要CIGB可以扩展并满足质量要求，古巴西港岛线继续独家制造和供应的疫苗， ”松露联合创始人兼董事长ABIVAX菲利普Pouletty告诉古巴标准。他拒绝透露具体哪些市场所涵盖的许可协议。

在一份新闻稿中它合并了三个法国生命科学公司，形成ABIVAX ，该投资者希望成为治疗性疫苗和抗病毒药物“的全球领导者”松露说。公司成立于十二月巴黎的ABIVAX有两个治疗性疫苗正在开发中，是在更多的收购谈判。

Poulletty说，他希望CIGB会以ABIVAX '管道贡献更多的产品，但他拒绝说明他们。

“在松露资本，我们很自豪两年与古巴，这是以其出色的医生和高质量的疫苗的讨论后，已成立ABIVAX ， ” Pouletty在新闻发布会上说。 “这是打算把法国和古巴在进步的前列，在治疗性疫苗领域的国际项目。 ”

CIGB ，国家控股BioCubaFarma最大的子公司，已与公司在中国，印度，加拿大和巴西，但是这是在欧洲市场的首次合作。在签署这个星期ABIVAX高管在哈瓦那许可协议， Norkis亚加莫拉莱斯， BioCubaFarma的业务发展总监，告诉Prensa拉提纳说CIGB将有助于乙肝疫苗，它已经开始销售在全球各个市场，其产能，而松露将有助于资本完成在欧洲和亚洲的临床研究，以及它的营销资源。

CIGB产品在ALBA成员国委内瑞拉，厄瓜多尔，玻利维亚和尼加拉瓜，以及在巴西，中国，越南和安哥拉出售，等等。

“我们在这两个研发和生产辅助技能使我们能够采取几种疫苗到在多年的国际市场来” ，亚加说，根据新闻报拉丁。

Pouletty告诉古巴准则， BioCubaFarma并不想成立一家合资企业这个时候，倒是有ABIVAX有一个“非常开放的精神，未来的合作。 ”

松露资本是一个13岁的独立风险投资公司550 €亿美元（ 7.54亿美元）根据管理及顾问，专门从事能源，信息技术和生命科学公司。该公司正在带领一个团队四种一般合伙人，菲利普Pouletty ，让 - 弗朗索瓦Fourt ，亨利Moulard ，和伯纳德 - 路易罗克斯的。

Pouletty的跟踪记录，包括创立和发展的生命科学公司，如Deinove （板Alternext ： ALDEI ） ， Carbios ，尔马特（板Alternext ： ALCAR ） ， Neovacs （板Alternext ： ALNEV ） ， Splicos ， Pharnext ， Plasmaprime ， Vexim和Wittycell 。他拥有29项专利，其中包括第二高创收的生命科学专利，斯坦福大学，和被引导的发明家名人堂的美国斯坦福大学礼堂在2012年。他从巴黎第六大学的医学博士，并且是法国生物技术，法国生物技术产业协会前主席。

HECHO恩古巴 - CIGB会产生药物在其位于哈瓦那设施

这三个法国生物技术公司松露放在一起，形成ABIVAX是Wittycell ， Splicos和Zophis 。

CIGB ，专门从事研究，开发和生产疫苗和抗病毒药物，已正与Wittycell上获得乙肝疫苗推向市场。该疫苗是在IIb期临床试验在慢性B型肝炎，从而导致肝硬化和肝癌。

Pouletty使他与CIGB在南非第一次接触四年前，他说他印象深刻的是古巴的生物技术实力。两年前，他的公司开始与CIGB谈判。

“我们花了一些时间来达成互利协议， ”他说。 “这是一个过程，可以是相对复杂的。 ”

正在开发其他ABIVAX产品包括抗病毒的药物用于艾滋病从Splicos ，抗HPV治疗性疫苗来治疗宫颈非典型增生和防止癌症从Wittycell的出现，和佐剂以增加NKT细胞和B细胞应答从Wittycell 。

yunqingabc

谢谢StephenW前辈，贡献这么多前沿的资料！

开心老黄牛